Accrued Expenses (Details) (USD $)	3 Months Ended		1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Apr. 30, 2014 Series C Preferred Stock
Accrued Expenses
Investor deposit		$ 500,000
Payroll and related costs	255,395	203,718
Clinical trials and drug development	84,403	73,500
Professional fees	110,420	295,000
Other	57,861	24,256
Accrued expenses	$ 508,079	$ 1,096,474
Accrued expenses
Shares issued	5,758,000		422,119